Amarillo Biosciences is midway in Phase 2 clinical study of interferon against H1N1

Amarillo Biosciences, Inc. (OTCBB: AMAR) today announced that a Phase 2 study of orally administered interferon-alpha for the prevention of influenza and winter colds has reached the midway point. The study in Perth, Australia achieved full target enrollment of 200 subjects and 98% of the subjects remain on study drug. Subjects in the study are receiving a lozenge containing interferon-alpha or a matching placebo once a day for 16 weeks. The average treatment time in the study to date is just over eight weeks. The first subject began treatment in May and the last subject will be completing blinded treatment in November, with final study results expected before the end of the year.

Study medication compliance has been excellent and is averaging 95% per week (i.e. 19 out of every 20 expected doses of study drug is being taken by the subjects). Safety has been excellent with no serious adverse events reported and only 4 drop-outs to date.

The H1N1 virus has been circulating in Perth since the study began. Presumably, some subjects in the study have been exposed to H1N1 virus. This Phase 2 clinical trial's objective is to determine the efficacy of low dose oral interferon in preventing and reducing the severity of infection with influenza viruses such as H1N1, among others.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
WHO announces recommended viral composition for 2025 influenza vaccines